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Abstract
Background: Undiagnosed, or diagnosed and untreated osteoporosis (OP) increases the likelihood that falls result
in hip fractures, decreased quality of life (QOL), and significant medical expenditures among older adults. We tested
whether a tailored dual energy x-ray absorptiometry (DXA) test result letter and an accompanying educational
bone-health brochure affected patient satisfaction, QOL, or OP knowledge.
Methods: The Patient Activation after DXA Result Notification (PAADRN) study was a double-blinded, pragmatic,
randomized trial which enrolled patients from 2012 to 2014. We randomized 7,749 patients presenting for DXA at three
health care institutions in the United States who were ≥ 50 years old and able to understand English. Intervention
patients received a tailored letter four weeks after DXA containing their results, 10-year fracture risk, and a
bone-health educational brochure. Control patients received the results of their DXA per the usual practices
of their providers and institutions. Satisfaction with bone health care, QOL, and OP knowledge were assessed
at baseline and 12- and 52-weeks after DXA. Intention-to-treat analyses used multiple imputation for missing
data and random effects regression models to adjust for clustering within providers and covariates.
Results: At 12-weeks 6,728 (86.8 %) and at 52-weeks 6,103 participants (78.8 %) completed their follow-up interviews.
The intervention group was more satisfied with their bone health care compared to the usual care group at both their
12- and 52-week follow-ups (standardized effect size = 0.28 at 12-weeks and 0.17 at 52-weeks, p < 0.001). There were no
differences between the intervention and usual care groups in QOL or OP knowledge at either time point.
Conclusions: A tailored DXA result letter and bone-health educational brochure sent to patients improved patient
satisfaction with bone-related health care.
Trial registration: Clinical Trials.gov Identifier: NCT01507662 First received: December 8, 2011.
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Background
Although only 10 % of Americans ≥ 50 years old are cur-
rently diagnosed with osteoporosis (OP) based on dual en-
ergy x-ray absorptiometry (DXA) testing [1], the lifetime
risk of a low-impact fracture is 40 % for older women and
13 % for older men [2]. Hip fractures, related to OP, are
associated with increased mortality and serious adverse ef-
fects on quality of life (QOL) and health care costs [3].
Many older adults know very little about their OP risks or
the rationale for screening to identify this silent dis-
ease [4, 5]. As suggested by health behavior theories,
like the Health Belief Model [6], knowledge of OP, its
risks and how to prevent or improve OP, is a first
step for patients in making bone health-related behav-
ior changes (i.e. getting adequate amounts of calcium,
vitamin D and weight-bearing exercise, taking appro-
priate pharmacotherapy, preventing falls).
Some randomized controlled trials (RCTs) have dem-
onstrated that educational interventions improve OP-
related knowledge [7–16]. Less is known about whether
such interventions affect patient satisfaction or QOL
[17, 18]. Most of these RCTs examining OP patient-
education interventions have been multifaceted or
lengthy [7, 12, 13, 15, 16], which are not scalable. To
date, only one RCT has examined the effect of an OP
education intervention on QOL, reporting a beneficial
effect after both three months and one year [16]. To our
knowledge only three studies have shown that patients
receiving educational or quality improvement interven-
tions were more satisfied with their bone-health care
than usual care groups [16, 19, 20]. However, two of
these studies were conducted only with older women
with an OP diagnosis [16, 19]. The other study only saw
improved satisfaction for timeliness in test result notifi-
cation but not in other measures of satisfaction (e.g. un-
derstanding DXA results or treatment options) [20].
Because tailored interventions individualized to the pa-
tient’s characteristics are more effective and preferred by
patients than standardized interventions [21, 22], we devel-
oped a tailored, pragmatic patient-activation intervention.
We reported that 90 % of older adults wanted to
receive their DXA results by mail [23]. Therefore, we
developed a DXA result letter and a bone-health edu-
cational brochure. We then designed and conducted a
pragmatic RCT to assess the impact of this interven-
tion on the pathways leading to appropriate pharma-
cotherapy, health behavior change, and satisfaction
with bone-health care, QOL, OP knowledge, and
cost-effectiveness (www.ClinicalTrials.gov Identifier
NCT01507662). This article describes the effects of
the intervention on three patient-reported outcomes:
satisfaction with bone health care, QOL, and OP
knowledge at 12 and 52 weeks post-baseline. We hy-
pothesized that the intervention would improve bone-
health care satisfaction and OP knowledge at both
time points, but would not change QOL.
Methods
Participants
Patients ≥ 50 years old presenting for DXA between
February 2012 and August 2014 at the University of Iowa
(UI), University of Alabama at Birmingham (UAB), and
Kaiser Permanente of Georgia (KPGA) were invited to
participate. We excluded non–English speakers and pris-
oners. Twenty dollar gift cards were provided after the
baseline interview.
Design and randomization
We used a double-blind, parallel, pragmatic RCT [24].
After patients completed their DXA and baseline inter-
views they were randomized based on their providers
using a computer program written in R [25]. Providers
were first ranked within sites based on the number of
DXAs they ordered in the previous two years, and then
they were randomized within sites using blocks of three
into three groups (1:1:1 allocation ratio). Patients of pro-
viders in the first group were assigned to the interven-
tion arm, patients of providers in the second group were
assigned to the usual care arm, and patients of providers
in the third group were randomized to either the usual
care or intervention arms (1:1 allocation ratio). We se-
lected three provider randomization groups to assess po-
tential spill-over effects on the main outcomes for usual
care patients of providers in the third group.
Procedures
At baseline, research assistants (RAs) at each site used
REDCap™ [26] computer assisted interviewing (CAI) soft-
ware to interview patients up to four weeks before or
three days after their DXA. All KPGA patients and half of
the UI patients completed these interviews in person. All
UAB patients and the remaining UI patients completed
their baseline interviews over the telephone. Three RAs at
UI mailed study materials to intervention patients.
Intervention
Intervention materials included a letter describing re-
sults of their DXA (lowest T-score and interpretation
[OP, low BMD or normal]), a graphic portrayal of their
10-year probability for a major osteoporotic fracture
(using FRAX®; https://www.shef.ac.uk/FRAX/), and a
bone-health educational brochure. These materials have
been described elsewhere [27, 28].
Outcomes
Twelve weeks and 52 weeks after their DXA, Iowa Social
Science Research Center interviewers telephoned pa-
tients at all three sites to conduct follow-up interviews
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using WinCATI 4 · 2 and 5 · 0 CAI software (Sawtooth
Technologies, Northbrook, IL). Interview questions have
been described elsewhere [24].
OP Care Satisfaction. This five-item scale assesses pa-
tient satisfaction with notification and understanding
DXA results, understanding OP treatments, receiving
adequate information to make an informed decision, and
overall satisfaction with bone-health care. Response op-
tions ranged from strongly agree to strongly disagree,
with summary scores ranging from 5 (least satisfied) to
25 (most satisfied). Four of these items were used in a
previous study [20], with a fifth item related to overall
satisfaction added for the current study. Because this
was the first use of the satisfaction with OP care scale
after its development and initial publication, we used ex-
ploratory factor and reliability analyses to explore its
psychometric properties. Those results revealed a simple
factor structure that was unidimensional with principal
factor loadings for each item ranging from 0.53 to 0.77,
and an internal consistency reliability (alpha) coefficient
of 0.77. At baseline, these items were only asked of pa-
tients with prior DXAs because they were irrelevant for
DXA naïve patients. All patients were asked these ques-
tions at the 12- and 52-week interviews.
Quality of Life. We used three QOL measures. The
first was the SF-1 (“In general, would you say your
health is excellent, very good, good, fair, or poor”), which
was scored as 95, 90, 80, 30, and 15 to reflect the under-
lying health utilities [29]. The second QOL measure was
the EQ-5D-3 L which has five items assessing difficulties
with mobility, self-care, activities of daily living, pain,
and mood (α = 0 · 70) [30, 31]. Responses (no difficulties,
some, or were completely impaired) were converted to
health utilities ranging from 0 (death) to 1 (best health
state) [30, 31]. The third QOL measure was the EuroQol
Visual Analog Scale (VAS) which asks patients to rate
their health from 1 (worst health state they can imagine)
to 100 (best health state they can imagine) [30, 31].
OP Knowledge. We used the 10-item “Osteoporosis and
You” scale [5, 32] to measure. The five responses ranged
from strongly agree (SA) to strongly disagree (SD), which
were collapsed into “correct” or “incorrect” responses.
Correct responses (SA or A for true or SD or D for false
statements) were coded “1” with incorrect responses
coded “0”. We summed the responses into a total score
(α = 0 · 68). We also examined the subscales (biological,
lifestyle, consequences, and prevention and treatment).
Statistical considerations and analysis
PAADRN was powered for guideline concordant treat-
ment as the clinical endpoint. Therefore, for the current
analysis, we calculated the statistical power that we
would have to detect a standardized effect size of 0.10
with p < 0.05 and attrition from baseline as high as 20 %.
Those calculations indicated that we would have
91.3 % power to detect such differences. We used
multiple imputation techniques to account for miss-
ingness (lost to follow-up, patient refused a specific
question or responded “don’t know”). We imputed
each item separately and constructed the outcomes
based on the imputed values. Our primary analysis
was based on intention-to-treat (ITT).
We first compared the outcome measures between the
intervention and control groups at baseline and at the two
follow-ups using t-tests. We then used linear random ef-
fects regression methods to adjust for patient clustering
within provider and for pre-specified covariates. For pa-
tient satisfaction, we first examined differences between
intervention and control groups at 12-weeks and 52-
weeks (baseline patient satisfaction was only asked for
those with prior DXAs). Among those with prior DXAs,
we adjusted for baseline satisfaction in separate models.
For QOL and OP knowledge we examined differences be-
tween baseline and 12-weeks, and baseline and 52-weeks.
We used Bonferroni methods to adjust for testing at two
time points (12- and 52-weeks) and for using three QOL
measures. We examined minimally important differences
(MIDs) defined distributionally as improvements ≥ 0.5
standard deviations (SD) [33]. For the EQ-5D utility score
we also used an anchor-based approach to predict utility
scores for the pairwise SF-1 comparisons (adjusting for
age, gender, and race).
We also investigated pre-specified heterogeneity of
treatment (HTE) effects. These included median splits
on preferred approaches to health care decision-making
and treatments [34], those with prior DXAs vs. those
without, those on OP-medications at baseline vs. those
who were not, those with a history of OP or osteopenia
at baseline vs. those who did not, site (UAB vs. KPGA
vs. UI), age (<65 vs. 65-75 vs. > 75), men vs. women,
Whites vs. non-Whites, education (high school or less
vs. some college vs. graduate school), self-rated health
(poor vs. fair vs. good vs. very good vs. excellent), having
COPD, depression, or prior fracture at baseline (vs. not),
FRAX risk (low vs. moderate vs. high), current smoker
vs. former smoker vs. never smoked, heavy vs. moderate
alcohol consumption, and median splits on weight-
bearing exercise.
In sensitivity analyses we used case-wise deletion in-
stead of multiple imputation. Because those results were
entirely consistent with the results presented below that
used multiple imputation, we only report the latter here.
With the Bonferroni adjustments, all p-values were 2-
tailed with ≤ 0.025 deemed statistically significant for pa-
tient satisfaction and OP-related knowledge, and < 0.0083
deemed statistically significant for the three measures of
QOL. Analyses were performed using SAS 9 · 4 (SAS
Institute Inc., Cary, NC).
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Results
Participant enrollment and characteristics
There were 20,397 potentially eligible patients, of whom
7,782 agreed to participate, were interviewed at baseline,
and were then randomized to either the intervention or
usual care groups (Fig. 1). Of these, 33 patients were
randomized in error and were removed from the study,
leaving 7,749 patients. Of these, 6,728 (86.8 %) com-
pleted the 12-week and 6,107 (78.8 %) completed the
52-week follow-up interviews. All 7,749 randomized par-
ticipants were included in the analysis using intent-to-
treat principles.
Table 1 presents baseline characteristics for all 7,749
participants. The mean age of our participants was
66 years, 84 % were women, 77 % were White, and 67 %
had previously undergone DXA. The intervention and
usual care groups were similar in age, sex, race, education,
and self-reported health. The usual care group, how-
ever, was more likely to have had OP prior to base-
line (p = 0.001), and to have had an index DXA indicating
low bone mineral density (BMD) or OP (p = 0.001).
Patient satisfaction with OP health care
Intervention patients had significantly greater (better)
levels of patient satisfaction with their bone-health
care than the usual care group at both 12-weeks (1.0
points, standardized effect size = 0.28, p < 0.001; Table 2)
and 52-weeks (0.6 points, standardized effect size = 0.21,
p < 0.001). Adjustments for clustering within providers
and the covariates did not alter these differences (1.02
points at 12-weeks and 0.63 at 52-weeks, p < 0.0005;
Table 3). Patients in the intervention group had 58 %
greater odds of having an MID improvement (AOR =
1.58, p < 0.0005) at 12-weeks and 34 % greater odds at 52-
Fig. 1 CONSORT Flow Diagram of PAADRN Study
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weeks (AOR = 1.34, p < 0.005). We observed comparable
results in all of the HTE comparison groups (not shown).
Additionally, we repeated the analyses at the item
level. In the pooled unadjusted and adjusted analyses at
both 12- and 52–weeks, the intervention group reported
significantly (p ≤ 0.002) higher satisfaction for each of
the five satisfaction items (data not shown). When strati-
fied by prior DXA use, the unadjusted results were sig-
nificant (p ≤ 0.03) for each of the five satisfaction items
with one exception (data not shown); at 52-weeks
among prior DXA users the intervention did not have a
significant effect (p = 0.14) on the item related to their
overall-satisfaction with bone-health care.
Quality of life
Intervention and control participants had similar
mean scores on all three QOL measures at baseline
(SF-1, p = 0.925; EQ-5D-3 L, p = 0.676; and, EuroQol
VAS, p = 0.590; Table 2). Mean scores for all three
QOL measures did not differ between groups at either 12-
or 52-weeks (Table 2). The changes from baseline to the
two follow-ups are not significant for all three QOL mea-
sures (data not shown). No significant differences were ob-
served in the random effects models, either, for any of the
three QOL measures (Table 3). Similarly, no significant dif-
ferences were observed for MID improvements for any of
the three QOL measures. In additional analyses at the item
level, no significant (p > 0.05) effects of the intervention
were observed for any of the QOL items (data not shown).
OP Knowledge
The intervention and usual care groups had the same
mean scores for OP knowledge (7.5, SD 1.9; Table 2).
OP knowledge increased significantly by 0.3 points for
both the intervention and usual care groups between
baseline and the 12- and 52-week follow-ups (p < 0.001),
but there was no difference in the amount of the in-
crease between the two groups (p =0.759 at 12-weeks
and p = 0.479 at 52-weeks; Table 2). Adjustment for pa-
tient clustering within provider, and for the covariates
did not alter these findings (Table 3). In additional ana-
lyses at the item level, no significant (p > 0.05) effects of
the intervention were observed for any of the OP know-
ledge items (data not shown).
Discussion
There is growing interest in engaging patients in their
own healthcare [35, 36]. Tailoring health communication
to be more patient-centered is becoming more common.
Yet, it is unclear whether greater access to tailored, DXA
testing communication results in any measurable im-
provements in patient reported outcomes. We designed
a, pragmatic, multi-site, RCT to evaluate the effects of a
tailored DXA result letter accompanied by a bone-health
Table 1 Baseline characteristics by treatment group among the







Age, mean (SD) 66.5 (8.4) 66.7 (8.2) 0.2461
Women, N (%) 3,259 (83.6) 3,230 (83.9) 0.7502
Race/Ethnicity
White, N (%) 2,981 (76.5) 2,954 (76.7) 0.6992
Black, N (%) 842 (21.6) 814 (21.1)
Other, N (%) 75 (1.9) 83 (2.2)
Education
Some high school, N (%) 161 (4.2) 140 (3.7) 0.7492
Completed high school, N (%) 819 (21.2) 836 (21.9)
Some college, N (%) 1,290 (33.4) 1,269 (33.2)
Completed college, N (%) 785 (20.3) 762 (19.9)
Graduate school, N (%) 809 (20.9) 814 (21.3)
Comorbid Conditions
COPD, N (%) 259 (6.7) 265 (6.9) 0.6802
Depression, N (%) 902 (23.2) 885 (23.0) 0.8782
Prostate cancer, N (%) 117 (18.3) 88 (14.2) 0.0482
Breast cancer, N (%) 416 (10.7) 612 (15.9) <0.0012
Health Habits
Current smoker, N (%) 295 (7.6) 295 (7.7) 0.8732
Past smoker, N (%) 1,478 (37.9) 1,388 (36.1) 0.0952
Current alcohol user, N (%) 1,768 (45.4) 1,808 (47.0) 0.1572
Self-reported Health Status
Excellent, N (%) 445 (11.4) 494 (12.8) 0.3292
Very Good, N (%) 1,443 (37.1) 1,373 (35.7)
Good, N (%) 1,280 (32.9) 1,253 (32.6)
Fair, N (%) 571 (14.7) 566 (14.7)
Poor, N (%) 150 (3.9) 159 (4.1)
Bone Health
Prior DXA, N (%) 2,606 (66.9) 2,590 (67.3) 0.7192
History of OP, N (%) 794 (20.6) 909 (23.8) 0.0012
History of OP treatment, N (%) 1,438 (36.9) 1,502 (39.0) 0.0552
Glucocorticoids Use, N (%) 593 (15.2) 576 (15.0) 0.7532
Study DXA Results
Normal, N (%) 1,133 (29.1) 990 (25.7) 0.0012
Low BMD, N (%) 2,052 (52.6) 2,066 (53.6)
Osteoporosis, N (%) 713 (18.3) 795 (20.6)
Lowest T-Score, mean (SD) -1.62 (1.1) -1.55 (1.1) 0.0021
10-year Fracture Risk (FRAX),
mean (SD)
12.0 (9.2) 12.3 (9.1) 0.1011
1P-value from Two-sample T-Test
2P-value is from Pearson Chi-square Test
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educational brochure on patient satisfaction with OP
care, QOL, and OP knowledge. Our results revealed
significantly improved patient satisfaction with OP
care in the intervention group compared to the usual
care group. Intervention patients had 58 % greater
odds of improving by at least an MID (0.5 SD) at 12-
weeks (p < 0.0005) and 34 % greater odds off improving by
at least an MID at 52-weeks (p < 0.005). However, we
found no differences in terms of QOL or OP knowledge
between the intervention and usual care groups.
These findings are important because, to our know-
ledge, this is the first positive study to include a com-
parison group, and to include patients with and without
OP. Patient satisfaction is recognized as an important di-
mension of healthcare quality. Medicare now evaluates
patient satisfaction [37] which will soon be used in de-
termining preventive service reimbursements for doctors
and hospitals. The intervention materials were pilot
tested to ensure comprehension as well as patient pref-
erences for information and design [27, 28]. Tailoring
test result communications to patients may improve
their satisfaction with other types of testing as well.
As important as the effect on satisfaction with OP care
is, failure to improve QOL or OP knowledge in our
study also must be considered. We did hypothesize that
the patient-activation intervention would not affect over-
all QOL because OP care is a small component of the
healthcare received by older adults who may have sev-
eral comorbidities. Indeed, OP would likely have min-
imal effects on QOL in the short-term until a fracture
occurs, at which point profound effects on QOL. Thus,
our results are consistent with prior studies of OP pa-
tient education interventions on QOL [11, 38], in which
only one reported a significant improvement among
Table 2 Unadjusted means (SDs) on all 7,749 PAADRN participants at baseline, 12- and 52-weeks using intention-to-treat (ITT)
Baseline 12-weeks 52-weeks
Intervention Control P-value Intervention Control P-value Intervention Control P-value
OP care satisfaction (5-25) 18.9 (2.7)a 19.1 (2.8)a 0.011 21.1 (3.2) 20.1 (4.0) <0.001 21.1 (3.2) 20.5 (3.8) <0.001
Quality of life
SF-1 (15/30/80/90/95; poor to excellent) 75.2 (23.8) 75.1 (24.1) 0.925 74.6 (24.2) 74.8 (24.4) 0.746 74.5 (24.1) 75.4 (23.8) 0.132
EuroQol EQ5D-3 L utility score (0-1) 0.8 (0.2) 0.8 (0.2) 0.676 0.8 (0.2) 0.8 (0.2) 0.547 0.8 (0.2) 0.8 (0.2) 0.72
EuroQol visual analog scale of Euroqol (0-100) 78.1 (16.7) 78.3 (16.7) 0.590 77.5 (17.6) 78.2 (17.2) 0.083 77.7 (17.6) 78.2 (17.1) 0.244
OPc knowledge – scale score (0-10) 7.5 (1.9) 7.5 (1.8) 0.712 7.8 (1.6) 7.8 (1.6) 0.759 7.8 (1.6) 7.8 (1.6) 0.476
Biological risk factors 2.3 (0.9) 2.3 (0.9) 0.345 2.5 (0.8) 2.4 (0.8) 0.495 2.5 (0.8) 2.5 (0.8) 0.724
Lifestyle risk factors 1.8 (0.4) 1.8 (0.4) 0.807 1.9 (0.3) 1.9 (0.4) 0.089 1.9 (0.4) 1.9 (0.4) 0.327
Consequences 1.7 (0.6) 1.7 (0.6) 0.688 1.7 (0.5) 1.7 (0.5) 0.471 1.7 (0.5) 1.7 (0.5) 0.485
Prevention and treatment 1 (0.8) 1 (0.8) 0.974 1 (0.8) 1 (0.8) 0.726 0.9 (0.8) 0.9 (0.8) 0.832
aThese are means and standard deviations among those who had a DXA prior to baseline interview
Table 3 Regression coefficients for the intervention on satisfaction with OP care, QOL, and OP knowledge from the intention-to-treat
(ITT) random effects models (N = 7,749)
12-weeks 52-weeks
Crude Adjusted Crude Adjusted
OP care satisfaction (5-25)a Estimate 1.02* 1.02* 0.61* 0.62*
95 % CI ( 0.82, 1.22) ( 0.83, 1.22) ( 0.40, 0.82) ( 0.43, 0.82)
Quality of life
SF-1 (15/30/80/90/95; poor to excellent) Estimate 0.21 -0.05 -0.37 -0.66
95 % CI ( -0.74, 1.16) ( -0.93, 0.83) ( -1.33, 0.58) ( -1.52, 0.21)
EuroQol EQ5D-3 L, utility score (0-1) Estimate 0.00 0.00 0.00 0.00
95 % CI ( -0.01, 0.01) ( -0.01, 0.00) ( -0.01, 0.01) ( -0.01, 0.01)
EuroQol visual analog scale (0-100) Estimate -0.44 -0.59 -0.42 -0.47
95 % CI ( -1.13, 0.26) ( -1.23, 0.05) ( -1.18, 0.33) ( -1.18, 0.24)
OP knowledge scale score (0-10) Estimate 0.01 0.01 0.04 0.03
95 % CI ( -0.07, 0.1) ( -0.06, 0.08) ( -0.03, 0.12) ( -0.04, 0.09)
*p < 0.0005
aThese are models on outcomes at 12-weeks and 52-weeks without adjustment for baseline values
Edmonds et al. BMC Musculoskeletal Disorders  (2016) 17:369 Page 6 of 8
Malaysian women taking bisphosphonates [16]. More-
over, trials of OP therapies, which demonstrate reduced
fracture rates, seldom are powered to detect an effect on
QOL for some of the reasons noted.
The absence of an effect of the patient-activation inter-
vention on OP knowledge is surprising and contrary to
our expectations. Prior OP-education interventions have
reported significant improvements in knowledge [7–16].
In contrast, we found that OP knowledge significantly
increased in both intervention and usual care groups,
but that the magnitude of these improvements was the
same. This may be due to the measure of OP knowledge.
First, the reliability of the OP knowledge measure was
only marginally acceptable (α = 0.68) [39]. Second, this
was the first RCT to use the “Osteoporosis and You”
measure, and the two prior observational studies assessing
its psychometric properties included younger women and
not men [5, 32]. Third, significant practice effects (about
half of an additional correct answer) were observed and
these may have created a ceiling effect that constrained
our ability to detect short-term differences. Finally, the
null effect may be due to the fact that neither the patient-
activation letter nor the educational brochure were tar-
geted to the “Osteoporosis and You” measure, although
an ad hoc analysis of the four items most closely
reflecting the intervention did not reveal an effect ei-
ther (data not shown). Although several other measures
of OP knowledge were available when our study began,
we eliminated them because they were too long and
cumbersome [40, 41] or were designed for younger
women who did not have OP [42]. Improved measures
of OP knowledge are needed, particularly among those
known to have OP.
Despite its strengths, our RCT had limitations. First,
the patient satisfaction with OP health care scale had
not been used in RCTs designed to improve bone health.
Second, we did not use an OP-specific QOL measure,
which might have been more responsive to our patient-
activation intervention. Lastly, given the clinical centers
used, our study population may not have been represen-
tative of all osteoporosis patients.
Conclusion
In conclusion, because of increases in the number and
percentage of older Americans at risk for OP and hip
fractures, there is a growing need for better OP health
care and patient knowledge about the prevention, treat-
ment, and consequences of this disease that remains
silent until fracture. We developed a pragmatic and tai-
lored patient-activation intervention that improved OP
care satisfaction. Future research and quality improve-
ment projects should examine whether patient satisfac-
tion scores in other clinical domains or in general would
increase when providing patients with their test results
in a tailored manner.
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